Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782296 | 1.00 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1NR3C2 | |
| SCHEMBL3776287 | 0.88 | NFE2L2 (0.38) | NFE2L2CES2CES1TRPA1NR3C2 | |
| SCHEMBL3662353 | 0.88 | NFE2L2 (0.41) | NFE2L2TRPA1MAPT | |
| SCHEMBL3769663 | 0.88 | NFE2L2 (0.41) | NFE2L2TRPA1MAPT | |
| SCHEMBL3662395 | 0.88 | NFE2L2 (0.38) | NFE2L2CES2CES1TRPA1NR3C2 | |
| SCHEMBL3768892 | 0.88 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1 | |
| SCHEMBL3768896 | 0.88 | NFE2L2 (0.47) | NFE2L2CES2CES1TRPA1 | |
| SCHEMBL3768756 | 0.87 | NFE2L2 (0.41) | NFE2L2TRPA1TDP1 | |
| SCHEMBL3661934 | 0.87 | NFE2L2 (0.41) | NFE2L2TRPA1TDP1 | |
| SCHEMBL3659474 | 0.85 | MAOB (0.38) | NFE2L2CES2CES1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | NFE2L2 825/4885CES2 295/4885CES1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.